Data Bridge Market Research analyses that the neuromyelitis optica spectrum disorder (NMOSD) market was valued at USD 405.9 million in 2021 and is expected to reach USD 651.84 million by 2029, registering a CAGR of 6.10% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Neuromyelitis optica spectrum disorder (NMOSD) is a chronic brain and spinal cord ailment characterized by inflammation of the optic nerve (optic neuritis) and spinal cord inflammation (myelitis). It was once thought to be a monophasic condition, with periods of inflammation of one or both optic nerves and the spinal cord lasting only a few days or weeks and no recurrence beyond the initial episode. According to new research, most individuals who meet the existing criteria for NMOSD have many attacks separated by periods of remission. This condition is also termed as Devic disease.

Read More : https://www.databridgemarketresearch.com/reports/global-neuromyelit...

Opportunities

Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities of medication for symptomatic treatment of osteoarthritis. This will provide beneficial opportunities for market growth for neuromyelitis optica spectrum disorder (NMOSD). The pivotal phase III study of the experimental medication satralizumab for the treatment of neuromyelitis optica spectrum condition was announced by F. Hoffmann-La Roche Ltd in December 2019. The phase III clinical trial for neuromyelitis optica spectrum condition with inebilizumab (Anti-CD19 mAb) was finished in 2019. Viela Bio is the provider.

Launch of new products and therapies
The increasing number of new product launches and therapies for the treatment of the neuromyelitis optica spectrum disorder (NMOSD) is anticipated to create new market opportunities during the forecast period of 2022 to 2029. The advent of new therapies for the treatment of neuromyelitis optica spectrum syndrome poses a potential market opportunity. Bevacizumab and Alpha1-antitrypsin and Rituximab and Eculizumab are two new treatments in progression for the acute phase and prophylaxis, respectively.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the neuromyelitis optica spectrum disorder (NMOSD) market growth during the forecast period.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Scope
The neuromyelitis optica spectrum disorder (NMOSD) market is segmented on the basis of type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies
Neuromyelitis Optica Spectrum Disorder without Aquaporin-4 Antibodies
Treatment Type

Medication
Immunosuppressive Agent
C5 Protein Inhibitor
Monoclonal Antibodies
Corticosteroids
Others
Plasma Exchange Therapy
Immunoglobulin Therapy
Diagnosis
Imaging Tests
Magnetic resonance imaging (MRI)
Others
Blood Tests
Others
Dosage form

Tablets
Injections
Others
Route of Administration

Oral
Parenteral
Others
End-Users

Hospitals
Specialty Clinics
Homecare
Others
Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Regional Analysis/Insights
The neuromyelitis optica spectrum disorder (NMOSD) market is analysed and market size insights and trends are provided by country, type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the neuromyelitis optica spectrum disorder (NMOSD) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the neuromyelitis optica spectrum disorder (NMOSD) market because of the launch of new treatment options in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to presence of generic manufacturers in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share Analysis
The Neuromyelitis optica spectrum disorder (NMOSD) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neuromyelitis optica spectrum disorder (NMOSD) market.

Some of the major players operating in the neuromyelitis optica spectrum disorder (NMOSD) market are:

F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France), Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Zydus Cadila (India)
Boehringer Ingelheim International GmbH. (Germany)
Apotex Inc. (Canada)
AstraZeneca (U.K.)
Horizon Therapeutics PLC (Ireland)
Johnson & Johnson Private Limited (U.S.)
Bayer AG (Germany)
Sun Pharmaceutical Industries Ltd. (India)
LEO Pharma A/S (Denmark)
Bausch Health Companies Inc. (Canada)
Allergan (Ireland)
Eli Lilly and Company (U.S.)
Aurobindo Pharma (India)
Lupin (India)

Neuromyelitis Optica Treatment Market - Industry Trends and Forecast to 2028

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- [email protected]